Methods and compositions comprising at least one α3 βA4 nAChR antagonist or pharmaceutically acceptable salt thereof

A pharmaceutical composition comprising a therapeutically-effective amount of N-2,3,3-tetramethylbicyclo-[2.2.1]heptan-2-amine or pharmaceutically-acceptable salt thereof and at least one pharmaceutically-acceptable excipient in a modified-release formulation in a dosage form chosen from oral, intra-nasal, and transdermal forms;

• wherein:
• N-2,3,3-tetramethylbicyclo-[2.2.1]heptan-2-amine exhibits an IC50 value for the α3 β4 sub-type of nAChR ranging from 1.0=10-6 to 1×10-9 M or exhibits a potency for the α3 β4 nAChR sub-type at least two-times greater in comparison to at least one other nAChR sub-type;
• the composition produces a peak:trough plasma level ratio of greater than zero to less than about 4:1;
• the therapeutically-effective amount ranges from about 2 mg to about 12 mg per day;
• the composition minimizes at least one side effect chosen from effects on heart rate, blood pressure, vision, and bladder function associated with a conventional formulation of the at least one an α3 β4 nAChR antagonist or pharmaceutically-acceptable salt thereof;
• and
• N-2,3,3-tetramethylbicyclo-[2.2.1]heptan-2-amine or the pharmaceutically-acceptable salt thereof is the sole active pharmaceutical compound in the composition.